Autism is a neurodevelopmental disease, and its main symptoms are social deficiencies and compulsive behaviors. Cases range from mild to severe, and causes are both genetic and environmental. Researchers at Tel Aviv University have successfully treated autism in animal models with medical cannabis oil, improving behavioral and biochemical parameters.
In about 1% of all autism cases, a mutation in a single gene, called Shank3, is associated. While testing of medicinal cannabis traditionally begins with humans, in the current study PhD student Shani Poleg and Prof. Daniel Offen of TAU’s Sackler Faculty of Medicine, Felsenstein Medical Research Center and Sagol School of Neuroscience used animal models with a mutation in Shank3 to test the effectiveness of cannabis oil for alleviating symptoms of autism. The results of the surprising study were published in Translational Psychology published by Nature.
“We saw that cannabis oil has a favorable effect on compulsive and anxious behaviors in model animals,” says Shani Poleg. “According to the prevailing theory, autism involves over arousal of the brain which causes compulsive behavior. In the lab, in addition to the behavioral results, we saw a significant decrease in the concentration of the arousing neurotransmitter glutamate in the spinal fluid – which can explain the reduction in behavioral symptoms.”
Attempting to determine which components of cannabis oil alleviate symptoms of autism, the researchers found that THC, the main psychoactive compound in cannabis which is responsible for the euphoric sensation associated with its use, is effective in treating autism, possibly even in small quantities.
“Clinical trials testing cannabis treatments for autism usually involve strains containing very large amounts of CBD – due to this substance’s anti-inflammatory properties, and because it does not produce a sense of euphoria,” explains Poleg. “Moreover, the strains used for treating autism usually contain very little THC, due to apprehension regarding both the euphoria and possible long-term effects.”
“In the second stage of our study we inquired which active substance in cannabis causes the behavioral improvement, and were surprised to discover that treatment with cannabis oil that contains THC but does not contain CBD produces equal or even better effects – both behavioral and biochemical. Moreover, our results suggest that CBD alone has no impact on the behavior of model animals.”
Prof. Daniel Offen says, “Since cannabis is not defined as a medication, trials have already been conducted in children and adolescents with autism – without any preliminary studies addressing issues like the effect of cannabis on biochemical processes in the brain, spinal fluid or blood, and who can benefit from which type of cannabis oil. There is a great deal of misinformation on the subject of medicinal cannabis and autism, and Shani Peleg’s doctoral project represents pioneering basic research with regard to treating autism with cannabis oil.”
“This is an initial study,” concludes Poleg. “But we hope that through our basic research we will be able to improve clinical treatments. Our study shows that when treating autism with medicinal cannabis oil there is no need for high contents of either CBD or THC. We observed significant improvement in behavioral tests following treatments with cannabis oil containing small amounts of THC and observed no long-term effects in cognitive or emotional tests conducted a month and a half after the treatment began.”